Walgreen Co. to Acquire Home Infusion Unit from Express Scripts, Inc.

Walgreen Co. (NYSE, NASDAQ: WAG) today announced a definitive agreement in which Walgreens, through its subsidiary OptionCare Enterprises, Inc., will acquire Express Scripts, Inc.’s (NASDAQ: ESRX) Louisville, Ky.-based home infusion pharmacy division. Terms of the agreement were not disclosed. The acquisition will further expand Walgreens home infusion services by providing greater access for its patients and payors. The parties expect the transaction to close within 30 days.

CuraScript Infusion Pharmacy, Inc., a wholly-owned subsidiary of Express Scripts, is one of the nation’s largest providers of infusion services and for nearly 17 years has supported patients who require complex therapies including anti-viral, immune deficiency, inotropic, chemotherapy and pain management treatments. Walgreens will acquire each of CuraScript IP’s 12 facilities located in Alabama, Indiana, Kentucky, Missouri, Ohio and Tennessee.

“This acquisition further expands our national coverage in home infusion services,” said Paul Mastrapa, president of Walgreens-OptionCare. “CuraScript IP is highly regarded in the industry for its clinical expertise and commitment to exceptional patient care. We welcome this addition to our infusion pharmacy network and look forward to reaching even more patients with this combined high level of personalized therapy and support.”